Clinical trials: Moxifloxacin
Community Acquired Pneumonia
Study to Proof the Clinical and Bacteriological Non-inferiority of Ampicillin/Amoxicillin Versus Moxifloxacin in Hospitalized Patients With Non-severe Community-acquired Pneumonia
The purpose of this study is to prove the clinical and bacteriological non-inferiority of ampicillin/amoxicillin versus moxifloxacin in hospitalized patients with non-severe community-acquired pneumonia.
- Trial name
- PENCAP (NCT00887276)
- Testing
- Moxifloxacin, Ampicillin;Amoxicillin
- Where
- 8 sites in Germany
- Volunteers
- 290 people
- Sponsor
- University of Ulm
Infectious Diseases
A Study to Assess Efficacy and Safety of IV/PO Moxifloxacin in the Treatment of cSSSIs
The purpose of this study is to assess if a therapy with intravenous and oral moxifloxacin is as effective as a therapy with intravenous and oral amoxicilline/clavulanate in the treatment of complicated skin and skin structure…
- Trial name
- MERAK (NCT00828971)
- Testing
- Avelox (Moxifloxacin, BAY12-8039), Amoxicilline/clavulanic
- Where
- 22 sites in Italy
- Volunteers
- 16 people
- Sponsor
- Bayer
Chronic Bronchitis
Moxifloxacin Versus Amoxicillin Clavulanic Acid in Treatment of Acute Exacerbation of Chronic Bronchitis
A study to assess the safety and efficacy of moxifloxacin compared to that of amoxicillin-clavulanic acid for the treatment of subjects with acute exacerbation of chronic bronchitis.
- Trial name
- NCT00656747
- Testing
- Avelox (Moxifloxacin, BAY12-8039), Amoxicillin clavulanic acid
- Where
- 220 sites in Andorra, Argentina and 29 more
- Volunteers
- 1,372 people
- Sponsor
- Bayer
Amyotrophic Lateral Sclerosis
Study to Evaluate the QTC Interval in Healthy Volunteers Dosed With Dexpramipexole (QTC = Electrocardiogram (ECG) Interval Measured From the Onset of the QRS Complex to the End of the T Wave Corrected for Heart Rate)
To evaluate whether dexpramipexole prolongs the QTc interval when orally administered to healthy volunteers.
- Trial name
- NCT01511029
- Testing
- Dexpramipexole, Moxifloxacin
- Where
- United States
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Knopp Biosciences
Healthy
A Study to Evaluate the Effects of JNJ-54861911 on Electrocardiogram Intervals in Healthy Particiants
The purpose of this study is to evaluate the effects of JNJ-54861911 on the QT/QTc intervals in healthy participants, when administered at therapeutic (50 milligram [mg] once-daily) and supratherapeutic (150 mg once-daily) doses…
- Trial name
- NCT02152332
- Testing
- JNJ-54861911-Therapeutic Dose, JNJ-54861911 - Supratherapeutic Dose, Moxifloxacin
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Pneumonia
Avelox for Treatment of Elderly Patients With Community Acquired Pneumonia
This study was to assess the safety of sequential intravenous (IV)/oral (PO) moxifloxacin (Avelox®) compared with sequential IV/PO levofloxacin (Levaquin®) in the treatment of elderly subjects (aged \≥ 65 years) with…
- Trial name
- NCT00665327
- Testing
- Avelox (Moxifloxacin, BAY12-8039), Levofloxacin
- Where
- 77 sites in United States, Puerto Rico
- Volunteers
- 401 people
- Sponsor
- Bayer
Tuberculosis
Effect of PA-824 and of PA-824 Plus Moxifloxacin on the QTc Interval in Healthy Volunteers
This is a Phase I, single-center, double-blinded, randomized, placebo-controlled, five-period cross-over clinical study of PA-824 to evaluate the effect of PA-824 and of PA-824 plus moxifloxacin on cardiac repolarization (QT/QTc…
- Trial name
- NCT01674218
- Testing
- Moxifloxacin, PA-824
- Where
- United States
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Prolonged QTc Interval
Evaluation of Whether Deferiprone Affects QT Interval in Healthy Subjects
Randomized, single-dose, double-blind, placebo and active controlled, four-period crossover study to evaluate the effect of deferiprone on QTc prolongation after administration of a single therapeutic (33 mg/kg) and…
- Trial name
- NCT01860703
- Testing
- Deferiprone, moxifloxacin
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- ApoPharma
Abscess, Wound Infection
Comparison of Sequential IV/PO Moxifloxacin With IV Piperacillin/Tazobactam Followed by PO Amoxicillin/Clavulanic Acid in Patients With a Complicated Skin and Skin Structure Infection
Patients, who are considered suitable by their physicians to take part in this research, will have a physical examination (including an Electrocardiogram (ECG)), blood and urine samples taken, as well as a sample of the…
- Conditions
- Abscess, Wound Infection, Diabetic Foot, Ulcer
- Trial name
- NCT00402727
- Testing
- Moxifloxacin (Avelox, BAY12-8039), Piperacillin/Tazobactam & Amoxicillin/Clavulanic acid
- Where
- 123 sites in Austria, Belgium and 18 more
- Volunteers
- 813 people
- Sponsor
- Bayer
Infection
Therapy of Complicated Intra-Abdominal Infections With Moxifloxacin or Ertapenem
A study to compare the safety and efficacy of moxifloxacin to ertapenem in patients with intra-abdominal infections.
- Trial name
- NCT00492726
- Testing
- Moxifloxacin (Avelox, BAY12-8039), Ertapenem intravenous
- Where
- 52 sites in Argentina, Belgium and 12 more
- Volunteers
- 804 people
- Sponsor
- Bayer
Sinusitis, Bacterial Infections
Study to Evaluate the Efficacy and Safety of Moxifloxacin Versus Amoxicillin/Clavulanate in the Treatment of Acute Bacterial Rhinosinusitis
This is a clinical study organized to collect clinical data to better define the activity of some antimicrobials already marketed in Italy and in the rest of the world for the treatment of acute bacterial rhinosinusitis
- Trial name
- NCT00493038
- Testing
- Moxifloxacin (Avelox, BAY12-8039), Amoxicillin/Clavulanate
- Where
- 34 sites in Italy
- Volunteers
- 293 people
- Sponsor
- Bayer
Pneumonia
A Study to Assess the Efficacy and Safety of IV/PO Moxifloxacin in Subjects With Community-acquired Pneumonia
The purpose of this study is to assess if a therapy with oral and intravenous moxifloxacin is as effective as a therapy with intravenous ceftriaxone + intravenous azithromycin followed by oral amoxicilline/clavulanate and oral…
- Trial name
- NCT00717561
- Testing
- Avelox (Moxifloxacin, BAY12-8039), Ceftriaxone; Azithromycin; Amoxicilline/clavulanate; Clarithromycin
- Where
- 23 sites in Italy
- Volunteers
- 60 people
- Sponsor
- Bayer
Lung Diseases, Bronchitis, Chronic
Intermittent Moxifloxacin Therapy For The Prevention Of Acute Exacerbations In Patients With Chronic Bronchitis
Moxifloxacin, is being tested at approximately 60 study centres in 15 countries to determine if this drug, when taken periodically in addition to the patients normal treatment, is effective at reducing the number of flare-ups of…
- Trial name
- NCT00473460
- Testing
- Avelox (Moxifloxacin, BAY12-8039)
- Where
- 78 sites in United States, Andorra and 13 more
- Volunteers
- 1,404 people
- Sponsor
- Bayer
Parkinson's Disease
Cardiac Effects of Rotigotine Transdermal System in Subjects With Advanced-stage Idiopathic Parkinson's Disease
The purpose of this trial is to assess whether rotigotine has an effect on the electrical activity of the heart. Moxifloxacin infusion is used as positive control to assess assay sensitivity.
- Trial name
- NCT00292227
- Testing
- Rotigotine, Moxifloxacin infusion
- Where
- 2 sites in South Africa
- Volunteers
- 130 people
- Sponsor
- UCB Pharma
Pelvic Inflammatory Disease
Uncomplicated Pelvic Inflammatory Disease. Treatment With Moxifloxacin.
Comparison of various antibiotics in treatment of uncomplicated pelvic inflammatory disease
- Trial name
- MAIDEN (NCT00683865)
- Testing
- Ofloxacin, Avelox (Moxifloxacin, BAY12-8039)
- Where
- 77 sites in Denmark, Finland and 11 more
- Volunteers
- 749 people
- Sponsor
- Bayer
Amount of NKTR-118 in Blood, Variation in the Heart's Electrical Cycle
A Placebo-controlled Four Way Crossover Study to Asses the Effect of a Single Oral Dose of NKTR-118 on QTc Interval in Healthy Male Subjects
The purpose of this study is to evaluate the effects on QTc interval in healthy males when administered a single dose of NKTR-118 compared with placebo and moxifloxacin.
- Trial name
- NCT01325415
- Testing
- NKTR-118, moxifloxacin
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy
Pharmacodynamic Effects, Safety and Tolerability of Cilobradine, to Healthy Male and Female Volunteers, With an Intra-individual Comparison to Moxifloxacin in a Subset of Volunteers
Incidence of visual phenomena, heart rate at rest, safety (with particular emphasis on QT analysis of ECGs), and pharmacokinetic parameters
- Trial name
- NCT02264015
- Testing
- Cilobradine, low, film-coated tablets, Cilobradine, high, film-coated tablets, Moxifloxacin, film-coated tablets
- Volunteers
- 125 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease
A Study to Evaluate Efficacy and Safety Profile of Zabofloxacin Tablet 400mg and Moxifloxacin Tablet 400mg
The purpose of this study is to Evaluate the Efficacy and Safety Profiles of oral multiple dose of Zabofloxacin Tablet 400 mg.
- Trial name
- DW224-III-3 (NCT01658020)
- Testing
- Zabofloxacin, Moxifloxacin
- Where
- South Korea
- Volunteers
- 345 people
- Sponsor
- Dong Wha Pharmaceutical Co. Ltd.
Healthy
Influence of Pramipexole on the QT Interval of the ECG in Healthy Male and Female Volunteers
The objective of the study is to assess that pramipexole does not prolong the QT interval more than placebo
- Trial name
- NCT02262546
- Testing
- Pramipexole extended-release (ER) tablets, Pramipexole immediate-release (IR) tablets, Moxifloxacin
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy Subjects, Cardiac Repolarization
Phase 1 Study to Assess the Effects of EVP-6124 on the QT/QTc Interval in Healthy Subjects
The purpose of this study is to evaluate the effect of EVP-6124 at therapeutic and supratherapeutic concentrations on cardiac repolarization in healthy subjects.
- Trial name
- TQT (NCT01487135)
- Testing
- EVP-6124, Moxifloxacin
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- FORUM Pharmaceuticals Inc